Allison is Chief Executive Officer at Avillion LLP, a London-based drug development company focused on the co-development and financing of late-stage pharmaceuticals. A trained clinician with more than 30 years of senior leadership experience in the pharmaceutical industry, an expert in oncology drug development, she is now responsible for identifying high-potential drug opportunities to fund and operationalize clinical development programs through to regulatory approval. Previously, she held senior R&D roles at Wyeth, BMS, and Novartis and has secured numerous US and EU drug approvals. Allison also serves as a Non-Executive Director of Agenus Inc. plus Chair of Oxsonics. She is a Senior Advisor to Blackstone Life Sciences and a Special Advisor to Abingworth.
- Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
- Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
- Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023